Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma

  • Komohara Y
  • Noyori O
  • Saito Y
  • et al.
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

The c-fms proto-oncogene is also known as macrophage colony stimulating factor receptor (M-CSFR) or colony-stimulating factor-1 receptor (CSF-1R), and is expressed on several types of malignant tumor cells and myeloid cells. In the present study, we found that overexpression of M-CSFR was present in adult T-cell leukemia/lymphoma (ATLL) cases. M-CSFR signaling was associated with lymphoma cell proliferation, and M-CSFR inhibition induced apoptosis in lymphoma cells. The ATLL cell line ATL-T expressed M-CSF/CSF-1 and interleukin (IL)-34, which are both M-CSFR ligands. M-CSF and IL-34 expression was seen in ATLL cases, and co-expression of these ligands was detected in 11 of 13 ATLL cases. M-CSFR inhibition suppressed programmed death-1 and -2 ligand in ATL-T cells and macrophages stimulated with conditioned medium from ATL-T cells. Thus, an M-CSFR inhibitor may be useful as additional therapy against ATLL due to direct and indirect mechanisms.

Cite

CITATION STYLE

APA

Komohara, Y., Noyori, O., Saito, Y., Takeya, H., Baghdadi, M., Kitagawa, F., … Suzu, S. (2018). Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma. Journal of Clinical and Experimental Hematopathology, 58(4), 152–160. https://doi.org/10.3960/jslrt.18034

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free